EGFR Mutations Status For Non-Small-Cell Lung Cancer Patients

Ieva Mirskytė, Jūratė Kasnauskienė, Alvydas Česas, Loreta Radvinskienė Abstract With the advent of the molecular-targeted therapy, rapid progress has been made in the treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). EGFR mutations detection in tumor is important to determine an appropriate treatment of EGFR TK inhibitors. We investigated EGFR mutation status for patients…